Quarterly review – Changes to Prime Funds & Prime ETFs

Prime Funds is our list of recommendations in equity, debt, and hybrid mutual funds that are worth investing in. Prime Funds narrows down your choices from the thousands of funds that there are into a concise list of funds that span different styles. Prime Funds are selected based on performance, portfolios, and investment strategies. 

In this review, we have made changes in multiple Prime Funds categories. Please go through the report in detail to know the changes and the rationale.

About Prime Funds

Prime Funds is our list of best mutual funds across the equity, debt, and hybrid categories. We use Prime Ratings, our fund ratings, as a first filter. We then apply qualitative analysis to arrive at our fund recommendations. Prime Funds is an enduring list of funds that you can use at any time. You will always find a fund to meet any goal you’re looking to meet.

Different categories: Prime Funds are separated into buckets, based on risk level in equity & hybrid funds and timeframe in debt funds. Each of these draws from different SEBI-defined categories. We have classified them in a more user-friendly way than using the several dozens of SEBI categories. We do not go only by Prime Ratings but look at other factors as well to narrow the list and make the choices easy for you.

Different styles: In Prime Funds, we’ve aimed at providing funds that follow different strategies for you to mix styles and diversify your portfolio with ease. The ‘Why this fund’ for each Prime Fund will brief its strategy, why we picked it, and how to use it in your portfolio.

Direct plans: We have specifically given the direct plans in Prime Funds. If you wish to know whether it is ok for you to use the regular plan of the fund, check our Portfolio Review Pro tool periodically to know if you are with expensive regular plans.

Quarterly review: Our aim in reviewing the Prime Funds list every quarter is to ensure that we don’t miss any good opportunities that are coming up and we are not holding on to funds that are slipping. When we remove funds from the Prime Funds list, we tell you exactly what to do if you have invested in these funds. Funds we remove do not immediately call for a sell – it is just that they have slipped in performance marginally or there are better alternatives now. Unless our review tool says such funds are a ‘sell’, you can hold them (refer to our article on when to sell funds)

Using Prime Funds: You don’t need to hold every Prime Fund nor add every new fund we introduce to the list. Unless it fits your overall portfolio/strategy, or there is something lacking, there is little need for you to go on adding funds. Our idea of covering them in detail through some of our calls is to let you know the strategy, style, and suitability in different portfolios. It is not a specific call to buy right away, unless we mention that it is a ‘tactical’ or ‘timing’ call. If you need to build a portfolio using Prime Funds, use our Build Your Own Portfolio tool to make this easy for you.

Equity funds

Equity markets have remained upbeat, with fresh impetus coming from the US Fed’s big rate cut. We have already explained in detail on how we expect markets to perform in our recent equity outlook review.

In these markets, it’s tempting to juggle your portfolio around to either try to protect it or to capture more gains. We suggest you do neither.

  • As always, asset allocation, category allocation and style diversification come to the fore. The reason for bringing in these aspects in a portfolio is to protect downsides and to manage different market cycles. So, if your portfolio is properly allocated, stand by it. Refrain from micro-managing because you’re worried about what markets will do or trying to pick every opportunity there is.
  • If your asset allocation is out of alignment (use the Portfolio Review Pro to know what allocation your portfolio needs), only then make the necessary changes. Reduce exposure to what has moved higher than the intended allocation and reinvest in what is low. Where your mid-and-smallcap allocation has moved significantly (by at least 5-7 percentage points from the original allocation), reinvest in large-cap oriented funds if your equity exposure is within necessary limits or in Hybrid – Moderate risk funds if your equity is already on the higher side.
  • If you have low exposure to the mid-and-small caps (or even in equity itself), then you can still invest in high-risk aggressive funds. Even if this space has been strongly bullish, your low exposure will limit the impact of a correction. In fact, running an SIP through a correction will be especially helpful for you.
  • If you have lump-sums to invest, stagger this over the next 4-6 months. Pick funds that keep your portfolio’s asset and category allocation within necessary limits.

The changes we have made this quarter are as follows.

Equity  – Moderate, active

In this category, we are adding BNP Paribas Large Cap fund. This addition is to provide more fund options that follow the ‘growth’ style of investing. This BNP Paribas fund has been beating the Nifty 100 TRI steadily from around early 2023 on a 1-year return basis. This performance has pulled into the longer-term period as well, with 3-year performance also improving on a steady basis.

The fund’s strategy is a growth-based approach, though valuations are also a factor. It follows a top-down approach, playing on broader themes and drilling down to sectors and stocks that can benefit. The fund’s current portfolio is positioned towards consumption and industrials, which bode well for sustained outperformance over the long term.

Bear in mind that it is best to pair any large-cap based fund along with a Nifty 50 index fund, given that active funds still find it hard to outperform by a significant margin on a consistent basis.

We have made no other changes in this set. Canara Robeco Flexicap, as we noted last quarter, has been struggling. But near-term performance is starting to pick up and its portfolio appears well-positioned to eventually pick up.

Equity  – Aggressive, active

In this Prime Funds set, we are making two changes. The first is that we are shifting Kotak Multicap into this set, from the Equity – High Risk Turnaround. We added this fund in our June quarter review in the High Risk set as it had yet to complete 3 years and we wanted to be cautious. The fund has now entered Prime Ratings and continues to hold up its strong performance.

The second change is to add Baroda BNP Multicap fund. This fund is more aggressive than the other two multicap funds we have in this Prime Funds set. The fund has steadily begun to outperform the Nifty Multicap index over the past few quarters on a 1-year basis. It also sports a consistent record on a longer-term 3-year basis. However, given that it is more aggressive, the Baroda BNP fund tends to fall more and has a higher volatility than the other two multicap funds in our list.

Baroda BNP Multicap follows a growth-oriented style but considers valuations as well. It takes active sector calls and holds a very diffused portfolio with a large number of stocks; individual stock weights are not high. The fund is suitable for high-risk investors, and it is best to add another high-risk active value-style fund or a passive fund along with this in your portfolio.

We are not removing any fund from the list. However, we want to highlight the performance of HDFC Smallcap fund. This fund, earlier a chart-topper, has now dropped below both smallcap category average and the Nifty Smallcap 250 TRI in the past few months. While the underperformance is fairly steep, we are waiting it out for several reasons.

One, the smallcap space has seen a rapid and broad rally, with even companies with poor underlying fundamentals rallying smartly. Most companies have also seen valuations shoot up. For quality-conscious and valuation-centric funds like HDFC Smallcap, this sort of market is a hard one to navigate and will inevitably lead to underperformance. HDFC Smallcap has exited several stocks, for example, besides making minimal changes in several more. It also moved slightly more into cash earlier in the year.

Two, smallcap funds have become extremely erratic in their outperformance over each other or the index making it hard to arrive at any decisive conclusion on consistency or trends. Therefore, we are retaining HDFC Smallcap in Prime Funds. Please note that underperformance may continue for some more time; the fund is otherwise a solid performer and scores well on downside containment.

Given the lack of good, consistent funds in both the mid-cap and small-cap categories, we are sticking to aggressive multicap and thematic funds to bring in high-return options.

Equity – High risk turnaround

In this Prime Funds set, we moved Kotak Multicap out as explained above. We have now added Invesco India Focused in this set. This fund has especially picked up outperformance over the Nifty 500 TRI over the past 3 quarters and has captured upsides well. Part of this performance comes from its good mid-and-smallcap exposure, but it is not the only focused fund to bet on this space; peer funds with similar exposure have not done as well as the Invesco fund. However, given its aggressive stance, Invesco Focused is not the best at either containing downsides or volatility.

The fund follows a growth-oriented approach in its portfolio. But it can also take very contrarian or offbeat calls, given that it aims at picking stocks with growth promise even if the sector itself may be an underperformer or the stock may not be a market favourite.

We are adding this fund in this Turnaround set given the recency of its outperformance, which needs watching, and owing to the higher risk from its focused strategy. If you want to add this fund to your portfolio, start with lower allocations.

Equity – Strategic/thematic

In this category, we are now removing two funds – ICICI Pru Commodities and UTI Transportation and Logistics. You can continue to hold both these funds. Fresh exposure can be avoided for now. 

We added the UTI Transportation & Logistics fund in April 2022, when there was clear sign of the auto story turning around post Covid. A low base helped maximise returns. The annualised returns  for this fund from our call stands at 40.5% as opposed to broad market index Nifty 500’s 22.7% return for the same period. 

With the sector’s scorching earnings growth now stabilising and valuations turning premium, we believe that the entry point is no longer attractive. For those who have already entered the sector, there is still a case for holding, given that certain segments (premium vehicles, two-wheeler uptick) etc can provide some steam. If your exposure to this fund has swelled significantly from your original allocation, you can take out some profits and hold the rest. 

Our history with the ICICI Pru Commodities fund has been more complex. We first recommended it in April 2021, then advised booking profits in June 2022. Following a healthy correction, we reintroduced it to our recommendations in January 2023, believing that global political tensions would cause supply disruptions and keep commodity prices elevated for an extended period.

However, this scenario did not materialize as expected. While precious metals like gold did rally, ferrous and non-ferrous metals such as iron ore, aluminium, nickel, and zinc have all seen a decline in global prices, with copper experiencing only a marginal increase. Energy prices, in particular, have significantly decreased, with the World Bank Energy index falling 33% as of August 2024 from its average level for the quarter ending December 2022.

Despite these global trends, the ICICI Commodities fund benefited from the domestic rally in steel stocks and select cement stocks. From April 2021 to date, the fund has delivered an annualized return of 30.3%, outperforming both the Nifty 500 (22%) and the Nifty Commodities index (26%) over the same period.

Looking ahead, the outlook for the commodities sector appears less promising in the medium term. We’re currently seeing a global supply glut situation for energy and no real shortage in supply for other commodities, which may limit the upside potential for the sector. Given these circumstances, we recommend avoiding fresh exposure to the fund. For those who have held the fund since our first recommendation and haven’t taken profits yet, now might be a good time to consider realizing some gains.

Hybrid funds

We have made only one change in hybrid funds.

Hybrid Equity - Moderate risk

In this category, we are replacing Canara Robeco Equity Hybrid with Kotak Equity Hybrid. While a majority of the funds in this category have been outperforming the Nifty Hybrid Composite index, comparison with peers shows underperformance of many. 

On a rolling 1-year return basis (over the last 3 years), Canara Robeco has beaten peer average only 3% of the times. There can be multiple variables for performance to vary significantly in this category – one allocation to equity and debt; and two within that, exposure to mid and small cap or duration calls. On this count, Canara Robeco’s 73% equity is no different from Kotak.

Kotak though scored on higher mid and small-cap allocation. However, considering that Kotak beats the former over 3-year rolling return as well, we would prefer it for fresh exposure. Those who hold the Canara Robeco fund can hold it and avoid fresh exposure by way of SIPs. They can add Kotak if the prefer marginally higher risk or stick to ICICI Pru Equity and Debt which is already in Prime Funds. 

Debt funds

With the Federal Reserve cutting rates in the US, all eyes are on the RBI’s MPC meeting coming up next week. While the consensus is that a rate cut is required from the RBI, irrespective of what transpires, we have stated in our Debt Outlook review that yield falls are inevitable. 

While many of you may have seen very low returns on your funds in the past 2-3 years, the returns of funds are already reflecting the yield fall scenario. For example, the average 1-year return of corporate bond funds was under 4% in January 2023. The same is now 8.4%. Similarly, from 4% 1-year returns for short duration funds, returns have now improved to 8.1%. 

We have been consciously playing duration in the past few quarters, adding gilts as well as preferring funds with floating rate instruments to curtail volatility - ICICI Pru Short Term and ICICI Pru Banking & PSU Debt are examples. 

Debt funds – Short term & Debt Funds - Medium term

In this category, we have added one more floating rate fund, SBI Floating Rate Debt. This fund has dynamically managed its maturity anywhere between 1-7 years in the past 2 years. It holds majority in gilts and is able to dynamically shift maturities in these instruments. It has beaten its category 76% of the times on a rolling 1-year return basis. This fund is suitable for those with marginally higher timeframe (closer to 3 years or more) than typical short duration funds considering the high exposure to gilts and dynamic change in maturities. 

We have made one more change in the debt space by switching ICICI Pru Short Term Fund from the Debt – Medium Term to the Debt – Short Term category. Instead, ICICI Banking & PSU Debt has moved from the short-term category to medium-term category. This is in line with their residual duration. There is no need to make any change if you had entered with the time frame stated in our earlier classification. The duration at your entry point will only matter. 

Prime ETFs

Prime ETFs is our list of recommended ETFs in equity, debt, and gold. We look at multiple factors to draw up this list, ranging from short-term and long-term tracking error, expense ratio, trading volumes and usefulness of the index in a portfolio.

In this review, we have made changes in the thematic ETFs.

Strategy & thematic

We have added ICICI Prudential Nifty Private Bank ETF. The banking sector as a whole has been a subdued performer as earnings growth stalled and concerns arose over credit growth and deposit mobilisation to fund growth. However, market underperformance has helped valuations turn very attractive. The private banking segment is especially well-poised in terms of valuations versus growth potential, with heavyweights such as HDFC Bank and Kotak Mahindra Bank being long market underperformers.

We are removing Nippon India Auto ETF and ICICI Pru Nifty Commodities ETF from the list. The reasoning for removing these two themes is explained above in the Prime Funds section, under Strategic/Thematic – both themes do not present attractive entry points now. For those who have already invested in these two thematic ETFs, continue to hold. However, if exposure has swelled significantly from the original, you can book some profits to lock in gains.

You can view the full list of Prime Funds here.

You can view the full list of Prime ETFs here.

Disclosures & Disclaimers

More like this

4 thoughts on “Quarterly review – Changes to Prime Funds & Prime ETFs”

  1. I have similar view that PI has lately taken a momentum approach to recommendations. You chop and change based not on valuations, portfolio quality and economic outlook for the sector but on recent performance. No one expects you to get the recommendations right all the time but views should be based on not recent / momentum based indicators.

    1. To clarify – the changes we have made in Prime Funds are actually not that many. The only ‘momentum’ based calls we have taken is in the new category we have added (High Risk Turnaround) simply because, if we were to be very backward looking and wait for a long time for performance to show up, we miss a lot of good returns funds have offered. So we have specifically put these in a separate category. With the main Prime Funds themselves, there are quite a few funds that are have been underperformers, but we have retained them for their portfolio and strategy – like Can Robeco Flexicap, or HDFC Smallcap, or Kotak Emerging Equity…other funds like Invesco Contra have also gone through phases of underperformance and are nowhere near the top-rated, but we have not moved them out. So it’s always a call based on the extent of underperformance, the category itself, the market scenario, and the fund. – regards, Bhavana

  2. Commenting here after seeing one Invesco fund. Am one of those who had invested in Invesco Focused, but chickened out the wrong time — & after I divested, it performed zoomed. Fortunately, it was not a big %ge of my portfolio.
    Want to highlight another Invesco fund. Invesco Large & Midcap fund (earlier, Invesco India Growth). A few years back, this fund was moved out of prime funds. It has performed decently since (last 2 years) and I got benefited by staying put.
    The reason I am bringing out here, most funds go thru — ups & troughs. Some level of portfolio analysis, along with fund manager skills, may be required — before divesting based on 5* and/or other star ratings. I highlighted 2 examples: one where I got benefited, one where I didn’t.

    1. Thank you for sharing your experience! Yes, relying on ratings alone to make decisions can wrong 🙂 That is why we have separate buy/sell/hold calls in addition to ratings and why we have some lower-rated funds in Prime Funds. – regards, Bhavana

Leave a Comment

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free